(Q33429161)

English

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial (English)

1 reference

Europe PubMed Central

26 July 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

Stephan Stilgenbauer

9

object named as

Stephan Stilgenbauer

0 references

5

object named as

Peter Hillmen

0 references

2

object named as

Michael Hallek

1 reference

Europe PubMed Central

26 July 2017

Anne-Sophie Michallet

4

object named as

Anne-Sophie Michallet

1 reference

Europe PubMed Central

26 July 2017

author name string

Clemens M Wendtner

1

1 reference

Europe PubMed Central

26 July 2017

Graeme A M Fraser

3

1 reference

Europe PubMed Central

26 July 2017

Jan Dürig

6

1 reference

Europe PubMed Central

26 July 2017

Matt Kalaycio

7

1 reference

Europe PubMed Central

26 July 2017

John G Gribben

8

1 reference

Europe PubMed Central

26 July 2017

Andreas Buhler

10

1 reference

Europe PubMed Central

26 July 2017

Thomas J Kipps

11

1 reference

Europe PubMed Central

26 July 2017

Brendan Purse

12

1 reference

Europe PubMed Central

26 July 2017

Jennie Zhang

13

1 reference

Europe PubMed Central

26 July 2017

Sabine De Bedout

14

1 reference

Europe PubMed Central

26 July 2017

Jay Mei

15

1 reference

Europe PubMed Central

26 July 2017

Asher Chanan-Khan

16

1 reference

Europe PubMed Central

26 July 2017

publication date

14 January 2016

1 reference

Europe PubMed Central

26 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

26 July 2017

57

1 reference

Europe PubMed Central

26 July 2017

6

1 reference

Europe PubMed Central

26 July 2017

1291-1299

1 reference

Europe PubMed Central

26 July 2017

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Tumour lysis syndrome: new therapeutic strategies and classification

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

How does lenalidomide target the chronic lymphocytic leukemia microenvironment?

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1128540

21 January 2018

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elimination mechanisms of therapeutic monoclonal antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism of immunoglobulins

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suboptimal dosing of rituximab in male and female patients with DLBCL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Theoretical Model of γ-Globulin Catabolism

1 reference

https://pubmed.ncbi.nlm.nih.gov/26763349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/10428194.2015.1128540

1 reference

Europe PubMed Central

26 July 2017

0 references

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33429161&oldid=1869201786"